New pill targets Tough-to-Treat cancers in early trial
NCT ID NCT05826600
Summary
This early-stage study is testing a new oral drug called OMX-0407 in adults with advanced solid tumors that cannot be surgically removed and have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors in specific cancers like kidney, lung, and bladder cancer. The study will also track how the drug moves through the body and its effects on patients' quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Assistance Publique Hopitaux de Marseille- Hopital de La Timone
Marseille, France
-
CHU de Liège
Liège, 4000, Belgium
-
CHU de Toulouse
Toulouse, France
-
Centro Integral Oncológico Clara Campal
Madrid, 28050, Spain
-
Cliniques Universitaires Saint-Luc
Brussels, 1200, Belgium
-
Clínica Universidad de Navarra
Madrid, 28027, Spain
-
Clínica Universidad de Navarra
Pamplona, 31008, Spain
-
Gustave Roussy - Institut Gustave Roussy
Paris, France
-
Hospital La Fe de Valencia
Valencia, 46026, Spain
-
Hospital Universitario Gregorio Marañon
Madrid, 28007, Spain
-
Hospital Universitario Vall d'Hebrón
Barcelona, 08035, Spain
-
Hospital del Mar
Barcelona, 08003, Spain
-
ICO Hospitalet
L'Hospitalet de Llobregat, Barcelona, 08906, Spain
-
Institut de Cancerologie de Ouest (ICO) - Saint-Herblain
Nantes, France
-
Institut du Cancer Montpellier (ICM)
Montpellier, France
-
MD Anderson Cancer Center
Madrid, 28033, Spain
-
NEXT Oncology - Hospital Quironsalud Barcelona
Barcelona, Spain
-
NEXT Oncology - Hospital Universitario Quironsalud
Madrid, Spain
-
START Madrid - Hospital Fundacion Jimenez Diaz
Madrid, 28040, Spain
-
UNICANCER - Centre Oscar Lambret
Nantes, France
-
UNICANCER-Institut Bergonie - Nouvelle-Aquitaine
Bordeaux, France
-
Universitair Ziekenhuis Gent
Ghent, 9000, Belgium
-
Universite de Lyon - Centre Leon-Berard (CLB)
Lyon, France
-
ZAS Augustinus Afdeling Oncologische Research
Wilrijk, 2610, Belgium
Conditions
Explore the condition pages connected to this study.